Charles River Laboratories International (NYSE:CRL – Get Free Report) had its price target lifted by Evercore ISI from $260.00 to $265.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price would indicate a potential upside of 8.54% from […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) announced its earnings results on Wednesday. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07, Briefing.com reports. Charles River Laboratories International had a net margin of 11.27% and a return on equity of 18.15%. The […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) released its earnings results on Wednesday. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.07, Briefing.com reports. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. […]
Charles River Laboratories International (NYSE:CRL – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 10.900-11.400 for the period, compared to the consensus earnings per share estimate of 10.790. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the […]
State of New Jersey Common Pension Fund D decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,786 shares of the medical research company’s stock after selling 806 shares during the […]